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AbstrAct
Objectives To measure the incidence of movement side 
effects of antipsychotic drugs in adults with intellectual 
disability and compare rates with adults without 
intellectual disability.
Design Cohort study using data from The Health 
Improvement Network.
setting UK primary care.
Participants Adults with intellectual disability prescribed 
antipsychotic drugs matched to a control group of adults 
without intellectual disability prescribed antipsychotic 
drugs.
Outcome measures New records of movement 
side effect including acute dystonias, akathisia, 
parkinsonism, tardive dyskinaesia and neuroleptic 
malignant syndrome.
results 9013 adults with intellectual disability and 
a control cohort of 34 242 adults without intellectual 
disability together contributed 148 709 person-years data. 
The overall incidence of recorded movement side effects 
was 275 per 10 000 person-years (95% CI 256 to 296) 
in the intellectual disability group and 248 per 10 000 
person-years (95% CI 237 to 260) in the control group. 
The incidence of any recorded movement side effect was 
significantly greater in people with intellectual disability 
compared with those without (incidence rate ratio 1.30, 
95% CI 1.18 to 1.42, p<0.001, after adjustment for 
potential confounders), with parkinsonism and akathisia 
showing the greatest difference between the groups. 
Neuroleptic malignant syndrome, although occurring 
infrequently, was three times more common in people 
with intellectual disability-prescribed antipsychotic drugs 
(incidence rate ratio 3.03, 95% CI 1.26 to 7.30, p=0.013). 
Differences in rates of movement side effects between 
the groups were not due to differences in the proportions 
prescribed first and second-generation antipsychotic 
drugs.
conclusions This study provides evidence to substantiate 
the long-held assumption that people with intellectual 
disability are more susceptible to movement side effects 
of antipsychotic drugs. Assessment for movement side 
effects should be integral to antipsychotic drug monitoring 
in people with intellectual disability. Regular medication 
review is essential to ensure optimal prescribing in this 
group.
IntrODuctIOn
Movement (extrapyramidal) side effects, 
including acute dystonias, akathisia, parkin-
sonism and tardive dyskinaesia are a 
well-recognised complication of antipsychotic 
drugs which are thought to occur secondary 
to antagonism of dopamine D2 receptors in 
the striatum and mesocortex.1 Movement 
side effects can be distressing, disabling and 
difficult to treat and their presence is asso-
ciated with poor medication compliance, 
stigma and reduced quality of life.2
Intellectual disability (ID) is a lifelong 
condition characterised by global deficits in 
cognitive and adaptive functioning. People 
with ID experience relatively high rates of 
mental illness3 and many are prescribed anti-
psychotic drugs in the UK and worldwide. 
There has been renewed focus on the appro-
priateness of antipsychotic drug prescribing 
in people with ID following recent evidence 
that antipsychotic drugs are often used in 
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strengths and limitations of this study
 ► This study includes a very large number of people 
with and without intellectual disability who have 
been prescribed antipsychotic drugs.
 ► The Health Improvement Network is a UK primary 
care database that contains accurate recording 
of demographic and clinical information and drug 
prescribing.
 ► This is the first study to directly compare the rates 
of movement side  effects of antipsychotic drugs 
between people with intellectual disability and those 
without, and offers new insights into the risk:benefit 
ratio of antipsychotic drug prescribing to people with 
intellectual disability.
 ► Recording of movement side effects of antipsychotic 
drugs in primary care has not been validated.
 ► Antipsychotic drugs prescribed outside primary 
care and movement side effects identified in other 
settings may not have been recorded by our method.
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the absence of an underlying diagnosed mental illness,4 
in many cases in an attempt to manage challenging 
behaviour, despite a lack of evidence that they are effec-
tive in this context.5 There has been relatively little formal 
investigation of antipsychotic drug side effects in people 
with ID and most of our knowledge is extrapolated from 
studies conducted in people of average intelligence. 
People with ID are often considered to be at greater risk 
of antipsychotic drug-induced movement side effects 
than people without ID6 but no studies directly compare 
rates between the two groups. Furthermore, knowledge 
of a specific mechanism that might underpin any associa-
tion between ID and movement side effects extends only 
to a vague theory that organic brain dysfunction makes 
centrally mediated side effects of psychotropic drugs 
more likely.7
We undertook a cohort study using a large nation-
ally representative database to compare the incidence 
of recorded movement side effects in adults with and 
without ID who are prescribed antipsychotic drugs.
MethODs
Data source
Data were obtained from The Health Improvement 
Network (THIN), a large UK primary care database that 
contains the electronic health records of more than 
3.7 million active patients in over 550 general practices 
(http://www. epic- uk. org/ our- data/ our- data. shtml). 
The patients included in the database are representa-
tive of the UK population in age, sex and morbidity and 
mortality.8 9 The vast majority of people with intellec-
tual disability in the UK live in the community and are 
registered with a general practitioner (GP; primary care 
physician) who provides routine and ongoing care and 
who acts as gatekeeper for hospital-based specialists, 
including psychiatrists. The THIN database contains clin-
ical records added by GPs using a clinical dictionary of 
Read codes. Read codes are standardised clinical terms 
that can be used as shorthand for clinicians to record 
certain patient characteristics (such as occupation and 
living circumstances) and the content of a consultation.10 
Individual Read codes exist to cover the variety of signs, 
symptoms and diagnoses that an individual may have, as 
well as test results and surgical or therapeutic treatments. 
Recording of illness in primary care records has been 
shown to be accurate and all prescribed medication must 
be issued through the electronic system. National Health 
Service drug budgets flow through primary care and 
GPs issue most prescriptions directly, including those for 
psychotropic drugs. The primary care record therefore 
is a suitable means of conducting pharmacoepidemiolog-
ical research.
THIN data are pseudonymised at source and made 
available to researchers who have purchased a license. 
THIN has overall ethical approval to collate data and this 
study received approval from the THIN Scientific Review 
Committee (reference 14–071).
study cohort
For this study, all adults with recorded ID and a history 
of oral antipsychotic drug prescription were extracted 
using a previously defined and tested list of diagnostic 
Read codes (including codes for ID and conditions asso-
ciated with ID) and antipsychotic drug codes,4 based 
on chapters of the British National Formulary. General 
practitioners are incentivised by the Quality Outcomes 
Framework to keep a register of people with ID which 
improves recording in the database. The study period was 
1 January 1999 to 31 December 2014. Entry to the cohort 
was set as the date of the first antipsychotic drug prescrip-
tion issued after the latest of; registration with the GP 
practice contributing data; the patient’s 18th birthday; the 
start of the study period; the date the practice achieved 
compliance with standard measures of data quality.11 12 
People contributed person-years (PYs) of data from entry 
to cohort exit. Exit from the cohort was defined as the 
first of: the final antipsychotic drug prescription plus the 
length of the prescription; deregistration with the GP 
practice contributing data; the end of the study period 
or death.
A comparison cohort of people prescribed antipsy-
chotic drugs but without ID was extracted using stratified 
sampling within each GP practice with frequency matching 
to ensure similar population-level characteristics across 
the two cohorts in terms of age, gender and year of anti-
psychotic prescription. Up to six people without ID were 
selected for every person with ID and the same criteria 
were used to define cohort entry and exit.
A Read code list for movement side effects was devel-
oped using previously described methodology and 
applied to the cohort to determine incidence of move-
ment side effects13 (see online supplementary data). 
Movement side effects were categorised as acute dysto-
nias, akathisia, parkinsonism or tardive dyskinaesia in 
accordance with orthodox classification. A separate cate-
gory was established for neuroleptic malignant syndrome, 
being a very specific adverse effect and a further category 
included for broad codes which could not be sub-cate-
gorised. Prescriptions for selected antimuscarinic drugs 
(procyclidine, orphenadrine, trihexyphenidyl) were used 
as proxy indicators of movement side effects in those 
prescribed antipsychotic drugs. People were defined as 
having a history of movement disorder if a relevant Read 
code was applied (or antimuscarinic drug prescribed) 
prior to cohort entry or within 6 months of registration 
with the practice, as this has been shown to improve the 
validity of incidence calculations.14
covariates
Sociodemographic covariates included age, sex, calendar 
year and the Townsend Deprivation Score (a composite 
score in fifths based on postcode and census recording 
of local unemployment, car ownership, home ownership 
and overcrowding).15 Other covariates included history 
of antipsychotic use at cohort entry, antipsychotic average 
daily dose and days on treatment between the start and 
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end of follow-up. Average daily dose was measured as 
chlorpromazine equivalents to account for polypharmacy 
and those who switched drugs during follow-up. Where 
we were unable to extract daily dose data (for example, in 
the minority of cases where the duration of a prescription 
was not recorded) the prescribed dose for the previous 
or subsequent prescription for the same drug and formu-
lation was used. It was not possible to estimate the daily 
dose for 5% of prescriptions, and these were excluded 
from the study. Prescriptions for drug doses above three 
times the upper licensed limit were excluded as probable 
coding errors (<1%).
statistical analysis
Multivariable mixed Poisson regression was used to calcu-
late incident rates of movement disorders during exposure 
to antipsychotic drugs in people with and without ID by 
calendar year, adjusted for any temporal changes in age 
and sex. Incidence rate was defined as the number of 
new events of interest/the duration that the cohort was 
at risk. First we were interested in the incidence of new 
cases of any movement disorder. Participants exited the 
cohort when they were first diagnosed with any move-
ment disorder as they were no longer considered at risk 
of a new diagnosis after this date. For calculating the 
incidence of subtypes of movement side effect, partici-
pants exited the cohort after they were diagnosed with 
the type of movement side effect of interest as they were 
no longer considered at risk of that type of movement 
side effect after that date. They remained in the cohort 
for the purposes of being diagnosed with other types of 
movement side effect as an individual participant may 
develop more than one type of movement side effect of 
antipsychotic drug.
General practice was included as a random effect to 
account for any data clustering. Calendar year was initially 
modelled as a continuous variable and we then used the 
likelihood ratio test to compare this with a model in which 
year was entered as a categorical variable to examine the 
possibility of non-linear time trends.
Multivariable mixed Poisson regression was also used 
to compare the rates of movement disorder during expo-
sure to antipsychotic drugs in people with and without 
ID, adjusted for covariates. We conducted a sensi-
tivity analysis where we restricted the analysis to time 
periods when people were exclusively prescribed first or 
second-generation antipsychotic drugs, and further when 
we restricted the analysis to times when only risperidone 
was prescribed. All analyses were repeated after excluding 
people with a diagnosis of idiopathic Parkinson’s disease.
We considered a p value of 0.05 to be statistically signif-
icant (two-tailed) and used Stata V.13 for all analyses 
(StataCorp).
results
In total, 9039 people with ID met inclusion criteria and 
were matched to 34 242 people without ID, and together 
contributed 148 709 PYs data. The two cohorts were 
similar in terms of age, sex, level of social deprivation and 
history of movement disorder at cohort entry (table 1). 
The prevalence of movement disorder at baseline was 
slightly higher for people with ID and a history of antipsy-
chotic use (31%) compared with those without ID and a 
history of antipsychotic drug use (24%) but the propor-
tions of those with a history of movement disorder without 
antipsychotic drug use were equal (6%) at cohort entry. 
Average daily dose of antipsychotic was similar between 
the two groups but those with ID had longer time periods 
between their first and last antipsychotic prescription and 
more days on treatment between those dates. Table 2 
shows the distribution of antipsychotic drugs prescribed 
to the study cohort. Risperidone was the most common 
drug prescribed in the ID cohort (28.5% prescriptions 
to people with ID, 14.7% prescriptions in the non-ID 
cohort); other drugs were prescribed in roughly equal 
proportions between the two groups.
The overall incidence of recorded movement 
side effects was 275 per 10 000 PYs (95% CI 256 to 296) 
in the ID group and 248 per 10 000 PYs (95% CI 237 to 
260) in the non-ID group (table 3). Parkinsonism was 
the most commonly recorded movement side effect in 
both groups. After adjustment, the incidence rate of any 
movement disorder was 30% higher in people with ID 
compared with those without ID (incidence rate ratio 
1.30, 95% CI 1.18 to 1.42, p<0.001). Similar differences in 
movement side effect recording were noted when defined 
by diagnostic Read codes or by proxy, using prescription 
for antimuscarinic drugs. The incidence rates of akathisia, 
parkinsonism and neuroleptic malignant syndrome were 
significantly higher in those with ID compared with those 
without ID.
Analysis restricted to periods when people were exclu-
sively prescribed first or second-generation antipsychotic 
drugs did not change the results; movement side effects 
were still significantly more likely to be recorded in 
people with ID compared with those without (table 4). 
Excluding people with Parkinson’s disease from the 
analysis (n=451) had no meaningful effect on any of the 
results.
Time trend analysis showed that the incidence of 
recording of movement side effects in those prescribed 
antipsychotic drugs fell significantly over the course of 
the study period in both groups (figure 1); each calendar 
year was associated with a 5% decline in the recording 
of movement side effects in people with ID (95% CI 2% 
to 8%, p<0.0001) and a 7% decline in people without 
ID (95% CI 5% to 9%, p<0.001), after accounting for 
changes in cohort age and sex. Prescriptions for antimus-
carinic drugs declined by 3% per year in people with ID 
(95% CI 1% to 5%, p=0.002) and 5% per year in people 
without ID (95% CI 4% to 7%, p<0.001). Average daily 
antipsychotic dose, measured in chlorpromazine equiva-
lents, remained broadly constant during the study period 
(data not shown).
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Table 1 Cohort characteristics
ID cohort Non-ID cohort
Total number (%) 9039 (21) 34 242 (79)
Male, n (%) 5279 (58) 18 825 (55)
Average age, years (SD) 42 (16) 44 (16)
Townsend score, n (%)
  1 1403 (16) 4860 (14)
  2 1752 (19) 5119 (15)
  3 1948 (22) 6481 (19)
  4 1942 (22) 8189 (24)
  5 1563 (17) 7911 (23)
  Missing 417 (5) 1619 (5)
History of antipsychotic use at cohort entry, n (%) 6684 (74) 16 227 (47)
History of movement disorder at cohort entry, n (%) 2192 (24) 4946 (14)
History of movement disorder without antipsychotic use at cohort 
entry, n (%)
136/2355 (6) 1038/18 015 (6)
History of movement disorder and antipsychotic use at cohort entry, 
n (%)
2056/6684 (31) 3908/16 227 (24)
Total person-years between first and last antipsychotic prescription 44 696 104 014
Median years between first and last prescription (IQR) 3.5 (1.2 to 7.9) 1.3 (0.19 to 4.4)
Median years on treatment between first and last prescription (IQR) 2.6 (0.76 to 6.3) 0.67 (0.15 to 2.5)
Average daily dose, CLZE (SD) 135 (156) 139 (146)
CLZE, chlorpromazine equivalents; ID, intellectual disability.
DIscussIOn
People with ID have long been considered at greater risk 
of adverse side effects of antipsychotic drugs. However to 
date, very little evidence has been presented to substan-
tiate this belief. Our data suggest that people with ID are 
more likely to experience movement side effects of anti-
psychotic drugs; this finding is robust and persists when 
movement side effects are defined by diagnostic Read 
code alone and when they are measured using prescrip-
tion of antimuscarinic drugs as proxy.
Most people in our cohort received a second-genera-
tion antipsychotic drug. The types of drugs that were 
prescribed in our study were broadly similar between 
the group with ID and the group without, and were 
consistent with other recent data examining antipsy-
chotic prescribing in community-dwelling adults living 
in the UK.16 The exception was risperidone, which 
was prescribed more frequently to people with ID; this 
accords with other studies17 and is likely to reflect an 
attempt by clinicians to prescribe the antipsychotic with 
greatest (although still limited) evidence of benefit for 
challenging behaviour in people with ID.5 18 The differ-
ence in incidence of movement side effects between 
people with and without ID remained when first and 
second-generation agents were considered separately, 
and when risperidone was considered alone, suggesting 
that headline differences between the groups were not 
due to different prescribing practices.
Although their improved movement side effect profile 
has been considered a major advantage of second-gen-
eration antipsychotic drugs, more recent evaluation 
of the evidence suggests that the initial enthusiasm for 
second-generation agents was misplaced and largely 
based on studies that made unequal comparisons between 
second-generation and high-potency first-generation 
drugs.19 20 In this study, we did not set out to compare 
movement side effects between first and second-gen-
eration agents but we observed that the prescription of 
second-generation agents was associated with a slightly 
lower incidence of recorded movement side effects in 
people with and without ID; clearly further work is needed 
to provide definitive data on this contentious aspect of 
antipsychotic drug side effects.
There is a lack of work with which we can directly 
compare our results; previous studies that investigate 
movement disorders in people with ID who take anti-
psychotic drugs have used differing methods to define 
and ascertain movement disorder, selected particular 
populations (often convenience sampling those residing 
in institutions) and tend to report point prevalence 
figures. None have directly compared rates of move-
ment side effect in people with ID to controls without ID. 
Nevertheless, it is clear that antipsychotic drug-induced 
movement side effects are reasonably common in people 
with ID. In once recent study of hospitalised patients with 
borderline-mild ID and challenging behaviour, almost 
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half were found to have a movement disorder, and the 
presence of movement disorder was more likely in those 
prescribed antipsychotic medication.21 The most common 
type was parkinsonism, as in our study. De Kuijper and 
colleagues in the Netherlands report that just over half of 
their sample with ID who had been taking antipsychotic 
drugs for more than a year had evidence of movement 
side effects.22
It is interesting that in our study the rates of recording 
of tardive dyskinaesia were relatively low and it was not 
more frequently recorded in people with ID. Previous 
work has shown tardive dyskinaesia to be common; one 
study of institutionalised adults with ID taking long-term 
antipsychotic drugs found a prevalence rate of tardive 
dyskinaesia of 45%.23 Spontaneous dyskinaesias are 
also common in people with ID24 and it is possible that 
drug-induced tardive dyskinaesia may be misinterpreted 
as part of the underlying ID and under-recorded, an 
example of ‘diagnostic overshadowing’. Conversely, it is 
also possible that background dyskinaesia related to ID 
might be misinterpreted as being the result of antipsy-
chotic drugs. Several assessment scales are available for 
measuring movement side effects of antipsychotic drugs 
and may be utilised in monitoring, although there are 
obvious challenges in assessment of subjective symptoms 
(such as akathisia) people with ID who may have limited 
understanding and verbal communication ability.25–27
Neuroleptic malignant syndrome is a rare idiosyncratic 
complication of antipsychotic therapy consisting of fever, 
muscle rigidity, autonomic dysfunction and alterations in 
cognitive state. We found a significantly increased inci-
dence of neuroleptic malignant syndrome among people 
with ID, although the low number of recorded events in 
the database means our results need to be interpreted with 
caution. An association between neuroleptic malignant 
syndrome and ID has been demonstrated previously28 29 
and this, combined with the seriousness of the condition 
(particularly in people with ID,29 30 warrants further atten-
tion.
We observed a decline in the recording of movement 
side effects in both groups over the past 15 years. It 
might be that clinicians have focused their attention on 
measuring and managing metabolic complications; the 
wide scale switch from first to second-generation anti-
psychotic drugs31 has partially contributed to an actual 
decrease in the rate of movement side effect; the clinical 
expectation of reduced movement side effects with newer 
drugs has reduced vigilance and recognition of these 
side effects.
strengths and limitations
This is the first study to directly compare the rate of anti-
psychotic drug-induced movement side effects between 
people with and without ID. Our findings are strength-
ened by the large numbers of people included and the 
sample being drawn from a representative commu-
nity population. UK general practices are incentivised 
to maintain an accurate list of people with ID, and as 
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prescriptions are also accurately recorded in THIN, our 
results are generalisable across settings to all people 
with intellectual disability who take antipsychotic drugs. 
We excluded depot antipsychotic preparations (and the 
small number of prescriptions that may have been issued 
in secondary care) and therefore might have slightly 
underestimated exposure to antipsychotic drugs.
A limitation of our work that is common across observa-
tional studies that the use routinely collected health data 
is the lack of direct validation of diagnoses. The Read 
code list for movement side effects was devised using a 
comprehensive methodology and with input from prac-
tising primary and specialist secondary care physicians 
but not tested against ‘gold standard’ methods for iden-
tifying movement side effects. We assume that relevant 
Read codes added to patient records during exposure 
to antipsychotic drugs represent adverse side effects; this 
may not always be the case and symptoms of movement 
disorder may arise independently or in response to other 
prescribed medications (such as antidepressants and 
antiepileptic drugs) that we did not measure. Our method 
measures only recorded side effects, that is, people must 
consult their GP for the side effect to be noted formally. 
Even when seen by a clinician, there is evidence that 
movement side effects might be missed.32 It is possible, 
therefore, that our results underestimate the true rate of 
movement side effect of antipsychotic drugs. How this 
might bias the comparison between ID and non-ID groups 
is not clear. People with ID have lower health literacy, 
lack knowledge of psychotropic drug side effects33 and 
may encounter barriers to accessing primary care34 and 
hence be less likely to present to primary care when expe-
riencing treatment side effects. Conversely, people with 
ID may be monitored more closely by carers or by proac-
tive GPs who recognise the higher health need in this 
group, for example, by offering an annual health check. 
Some cases of movement side effects may have not been 
recorded in the primary care database if people who are 
in contact with specialist services contact their psychiatrist 
directly rather than visiting their GP. Neuroleptic malig-
nant syndrome may be underestimated either because 
milder forms are missed or because it is more likely to be 
treated in the acute hospital.
Further work will be needed to elucidate the potential 
pathophysiological mechanism underlying the observed 
association between ID and movement side effects of anti-
psychotic drugs.
cOnclusIOns
Movement side effects are only one aspect of a number 
of antipsychotic drug adverse effects. They can impact 
medication compliance, quality of life and compound the 
stigma of mental illness and/or intellectual disability.35 36 
They can be difficult to recognise, to treat and, in the case 
of the tardive syndromes, can persist or even worsen on 
withdrawal of the offending drug. People with ID appear 
more susceptible to movement side effects of antipsychotic 
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Figure 1 Time trends in crude incidence rates of (A) movement side effect defined by Read code and (B) antimuscarinic drug 
prescription in people with and without ID prescribed antipsychotic drugs. ID, intellectual disability.
drugs than people without ID, and this should be consid-
ered when treatment decisions are made, especially given 
the relatively high rates of other comorbidities in this 
population. There is evidence that movement side effects 
of antipsychotic drugs are poorly assessed in people with 
ID who are under the care of secondary care services37; 
this situation must change if medication is to be used in 
the safest and most effective way possible.
Our data support a modest potential benefit of 
second-generation antipsychotic drugs in reducing the 
incidence of movement side effects, but more work is 
needed to confirm this finding, and it must be balanced 
against the increased propensity of second-generation 
agents to cause metabolic side effects.
There has been much recent public and professional 
interest in the prescription of antipsychotic drugs to 
people with intellectual disability and UK national policy 
supports attempts to reduce the prescribing of antipsy-
chotic drugs for challenging behaviour (https://www. 
england. nhs. uk/ wp- content/ uploads/ 2016/ 06/ stop-
ping- over- medication. pdf). We recently showed that 
reduction or discontinuation of antipsychotic drugs in 
people with ID and challenging behaviour (but without 
severe mental illness) risks harm as well as providing 
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potential benefits and advocate individual treatment 
decisions in this group.38 The current work informs 
the risk–benefit analysis undertaken as part of antipsy-
chotic drug prescribing in people with ID and reinforces 
the need for regular and effective medication review, 
which must include assessment of possible movement 
side effects.
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